[0015] Tretinoin is used topically for treating acne and its anti-ageing properties. It is also used to increase the penetration and therefore effectiveness of other topical treatments for the skin and hair.

[0016] This present invention seeks to provide a formulation for increasing hair growth, reducing hair thinning and promoting hair thickening by increasing the diameter of some or all of the hair follicles comprising administration to a scalp of a subject prior to, subsequently or concurrently the subject receiving platelet rich fibrin.

BRIEF SUMMARY OF THE DISCLOSURE

[0016a] In a first aspect of the present disclosure, there is provided a cosmetic method of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF) comprising administering a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the scalp of the subject.

[0016b] In another aspect of the present disclosure, there is provided a use of a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin in a cosmetic method to increase hair thickness, increase hair growth, reduce hair thinning and/or reduce hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF).

[0016c] In yet another aspect of the present disclosure, there is provided a formulation comprising, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin for the treatment of hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF).

[0016d] In a further aspect of the present disclosure, there is provided a use of a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin, in the manufacture of a medicament for increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF).

[0016e] In another aspect of the present disclosure, there is provided a cosmetic method of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss of the eyebrows and/or eyelashes of a subject comprising administering a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the eyebrows and/or eyelashes of the subject.

[0016f] In yet another aspect of the present disclosure, there is provided a use of a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin in a cosmetic method to increase hair thickness, increase hair growth, reduce hair thinning and/or reduce hair loss of the eyebrows and/or eyelashes in a subject.

[0016g] In a further aspect of the present disclosure, there is provided a formulation comprising, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin for the treatment of hair loss of the eyebrows and/or eyelashes of a subject.

[0016h] In another aspect of the present disclosure, there is provided a use of a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin, in the manufacture of a medicament for increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss of the eyebrows and/or eyelashes of a subject.

[0016i] In yet another aspect of the present disclosure, there is provided a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin for use in therapy.

[0017] In accordance with an example of the present disclosure, there is provided a cosmetic method of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss in a subject comprising administering a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.1 wt% to 1 wt% melatonin to the subject. Typically, the amount administered will be an effective amount. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0018] In accordance with an example of the present disclosure, there is provided a cosmetic method of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF) comprising administering a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.1 wt% to 1 wt% melatonin to the subject. Typically, the amount administered will be an effective amount. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0019] In accordance with an example of the present disclosure, there is provided a cosmetic method of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF) comprising administering a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.1 wt% to 1 wt% melatonin to the scalp of the subject. Typically, the amount administered will be an effective amount. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0020] In accordance with another example of the present disclosure, there is provided a cosmetic method of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss comprising administering a formulation comprising 0.01

wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the scalp of a subject prior to, subsequently or concurrently to administering platelet rich fibrin (PRF) to the scalp of a subject. Typically, the amount administered will be an effective amount. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0021] In accordance with another example of the present disclosure, there is provided a method of treatment of hair loss in a subject comprising administering a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the subject. Typically, the amount administered will be an effective amount. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0022] In accordance with another example of the present disclosure, there is provided a method of treatment of hair loss in a subject comprising administering a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the subject prior to, subsequently or concurrently to administering platelet rich fibrin (PRF) to the subject. Typically, the amount administered will be an effective amount. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0023] In accordance with another example of the present disclosure, there is provided a method of treatment of hair loss in a subject comprising administering a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the scalp of a subject prior to, subsequently or concurrently to administering platelet rich fibrin (PRF) to the scalp of a subject. Typically, the amount administered will be an effective amount. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0024] In accordance with another example of the present disclosure, there is provided a method of treatment of hair loss in a subject that has or will subsequently or concurrently receive platelet rich fibrin (PRF), the method comprising administering a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the scalp of a subject prior to, subsequently or concurrently to administering platelet rich fibrin (PRF) to the scalp of a subject. Typically, the amount administered will be an effective amount. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0025] In accordance with another example of the present disclosure, there is provided a use of a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to increase hair thickness, increase hair growth, reduce hair thinning and/or

reduce hair loss in a subject. Typically, the amount administered will be an effective amount. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0026] In accordance with another example of the present disclosure, there is provided a use of a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to increase hair thickness, increase hair growth, reduce hair thinning and/or reduce hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF). Typically, the amount administered will be an effective amount. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0027] In accordance with another example of the present disclosure, there is provided a use of a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to increase hair thickness, increase hair growth, reduce hair thinning and/or reduce hair loss prior to, subsequently or concurrently to administration of platelet rich fibrin (PRF) to a scalp of a subject. Typically, the amount administered will be an effective amount. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0028] In accordance with another example of the present disclosure, there is provided a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin for the treatment of hair loss in a subject. Typically, the amount administered will be an effective amount. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0029] In accordance with another example of the present disclosure, there is provided a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin for the treatment of hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF). Typically, the amount administered will be an effective amount. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0030] In accordance with an example of the present disclosure, there is provided a cosmetic method of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss in a subject comprising administering a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the subject.

[0031] In accordance with an example of the present disclosure, there is provided a cosmetic method of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss in a subject that has or will subsequently or concurrently

receive platelet rich fibrin (PRF) comprising administering a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the subject.

[0032] In accordance with an example of the present disclosure, there is provided a cosmetic method of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss in a subject that has or will subsequently or concurrently receive platelet rich fibrin (PRF) comprising administering a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the scalp of the subject.

[0033] In accordance with another example of the present disclosure, there is provided a cosmetic method of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss comprising administering a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the scalp of a subject prior to, subsequently or concurrently to administering platelet rich fibrin (PRF) to the scalp of a subject. Typically, the amount administered will be an effective amount.

[0034] In accordance with another example of the present disclosure, there is provided a method of treatment of hair loss in a subject comprising administering a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the subject. Typically, the amount administered will be an effective amount.

[0035] In accordance with another example of the present disclosure, there is provided a method of treatment of hair loss in a subject comprising administering a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the subject prior to, subsequently or concurrently to administering platelet rich fibrin (PRF) to the subject. Typically, the amount administered will be an effective amount.

[0036] In accordance with another example of the present disclosure, there is provided a method of treatment of hair loss in a subject comprising administering a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the scalp of a subject prior to, subsequently or concurrently to

administering platelet rich fibrin (PRF) to the scalp of a subject. Typically, the amount administered will be an effective amount.

[0037] In accordance with another example of the present disclosure, there is provided a method of treatment of hair loss in a subject that has or will subsequently or concurrently receive platelet rich fibrin (PRF), the method comprising administering a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the scalp of a subject. Typically, the amount administered will be an effective amount.

[0038] In accordance with another example of the present disclosure, there is provided a use of a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to increase hair thickness, increase hair growth, reduce hair thinning and/or reduce hair loss in a subject. Typically, the amount administered will be an effective amount.

[0039] In accordance with another example of the present disclosure, there is provided a use of a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to increase hair thickness, increase hair growth, reduce hair thinning and/or reduce hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF). Typically, the amount administered will be an effective amount.

[0040] In accordance with another example of the present disclosure, there is provided a use of a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt % finasteride and 0.01 wt% to 1 wt% melatonin to increase hair thickness, increase hair growth, reduce hair thinning and/or reduce hair loss prior to, subsequently or concurrently to administration of platelet rich fibrin (PRF) to a scalp of a subject. Typically, the amount administered will be an effective amount.

[0041] In accordance with another example of the present disclosure, there is provided a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin for the treatment of hair loss in a subject. Typically, the amount administered will be an effective amount.

[0042] In accordance with another example of the present disclosure, there is provided a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and

0.01 wt% to 1 wt% melatonin for the treatment of hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF). Typically, the amount administered will be an effective amount.

[0043] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the formulation is administered to the subject to areas affected by hair loss. It may be that the area affected by hair loss is selected from the group consisting of the scalp, beard, eyebrows, eyelashes and body hair. It may be that the area affected by hair loss is the scalp. It may be that the area affected by hair loss is the eyebrows. It may be that the area affected by hair loss is the eyelashes.

[0044] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the formulation is administered to the subject to areas of hair thinning. It may be that the areas of hair thinning are selected from the group consisting of the scalp, beard, eyebrows, eyelashes and body hair. It may be that the area of hair thinning is the scalp. It may be that the area of hair thinning is the eyebrows. It may be that the area of hair thinning is the eyelashes.

[0045] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.1 wt% to 1 wt% melatonin is administered to the scalp, eyebrows and/or eyelashes of a subject. It may be that the formulation further comprises latanoprost. Thus, it may be that a formulation comprising 0.01 wt% to 1 wt% finasteride, 0.1 wt% to 1 wt% melatonin, and 0.0005 wt% to 0.01 wt% latanoprost is administered to the scalp, eyebrows and/or eyelashes of a subject.

[0046] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein a formulation comprising 0.01 wt% to 1 wt% finasteride, 0.1 wt% to 1 wt% melatonin, and 1 wt% to 12.5 wt% minoxidil is administered to the scalp, eyebrows and/or eyelashes of a subject. It may be that the formulation further comprises latanoprost. Thus, it may be that a formulation comprising 0.01 wt% to 1 wt% finasteride, 0.1 wt% to 1 wt% melatonin, 1 wt% to 12.5 wt% minoxidil, and 0.0005 wt% to 0.01 wt% latanoprost is administered to the scalp, eyebrows and/or eyelashes of a subject.

[0047] In examples, the subject will not receive platelet rich fibrin (PRF). Therefore, it may be that the subject has not received and will not subsequently or concurrently receive platelet rich fibrin (PRF). It may be that the formulation is administered to the

subject to areas affected by hair loss, wherein the subject will not receive platelet rich fibrin (PRF). It may be that the formulation is administered to the subject to areas of hair thinning, wherein the subject will not receive platelet rich fibrin (PRF). It may be that the formulation is administered to the eyebrows and/or eyelashes of a subject, wherein the subject will not receive platelet rich fibrin (PRF). Preferably, the formulation is administered to the eyebrows of a subject, wherein the subject will not receive platelet rich fibrin (PRF).

[0048] In examples, the subject may have or may subsequently or concurrently receive platelet rich fibrin (PRF). The method may comprise administering platelet rich fibrin (PRF) to the subject. The platelet rich fibrin (PRF) may be administered to the subject (for example, by subcutaneous administration or injection). Typically, the amount administered will be an effective amount.

[0049] The platelet rich fibrin (PRF) may be administered to the subject prior to, subsequently or concurrently to administering the formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the subject. Typically, the amount administered will be an effective amount.

[0050] It may be that PRF is not administered to the scalp of the subject.

[0051] It may be that the PRF is administered to the scalp of the subject. Therefore, the subject may have or may subsequently or concurrently receive platelet rich fibrin (PRF) administered to their scalp. The method may comprise administering platelet rich fibrin (PRF) to the scalp of a subject. The platelet rich fibrin (PRF) may be administered to the scalp of a subject (for example, by subcutaneous administration or injection into the scalp). Typically, the amount administered will be an effective amount.

[0052] The platelet rich fibrin (PRF) may be administered to the scalp of a subject prior to, subsequently or concurrently to administering the formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the scalp of a subject. Typically, the amount administered will be an effective amount.

[0053] The formulation may be administered to the subject daily, and the PRF treatment may be provided to the subject at any point before, during, or after treatment with the formulation. For example, the PRF treatment may be provided to the subject 1, 2, 3, 4, 5, 6, or 7 days before, 14 days before, 21 days before, or 28 days before the subject is

[0062] For example, 10 mls of PRF in 0.1 ml aliquots may be injected in the areas of hair thinning.

[0063] Four sessions of PRF may be provided to the subject four weeks apart.

[0064] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the hair loss is caused by a condition selected from: androgenetic alopecia, telogen effluvium, alopecia areata and scarring hair loss.

[0065] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the hair loss is caused by a condition selected from: androgenetic alopecia, telogen effluvium, alopecia areata and lichen planopilaris.

[0066] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the hair loss is caused by androgenetic alopecia.

[0067] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the formulation comprises 2 wt% to 11 wt% minoxidil.

[0068] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the formulation comprises 0.1 wt% to 1 wt% finasteride.

[0069] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the formulation comprises 0.05 wt% to 0.5 wt% melatonin.

[0070] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the formulation comprises 0.1 wt% to 0.2 wt% melatonin. It may be that the formulation comprises 0.1 wt% melatonin.

[0071] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the formulation further comprises a prostaglandin analogue at an amount between 0.01 wt% to 5 wt%.

[0072] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the prostaglandin analogue is selected from the group consisting of: travoprost, bimatoprost, tafluprost and unoprostone.

[0073] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the prostaglandin analogue is latanoprost.

[0074] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the formulation further comprises a retinoic acid at an amount between 0.01 wt% to 2 wt%.

[0075] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the retinoic acid is tretinoin.

[0076] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the retinoic acid is not tretinoin.

[0077] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure, wherein the formulation does not comprise retinoic acid. Thus, it may be that the formulation does not comprise tretinoin.

[0078] The cosmetic method, use and/or formulation for use according to any one of the examples of the present disclosure in the form of an ointment, lotion and/or spray for topical administration.

[0079] There is provided a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin. The formulation may further comprise 1 wt% to 12.5 wt% minoxidil.

[0080] There is provided a formulation comprising 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin.

[0081] There may also be provided a pharmaceutical composition comprising the formulation according to the present disclosure and a pharmaceutically acceptable carrier.

[0082] Minoxidil, finasteride and melatonin are typically provided in the formulation in synergistically effective amounts.

[0083] The formulation may comprise at least 2 wt% minoxidil. The formulation may comprise at least 4 wt% minoxidil. The formulation may comprise at least 5 wt% minoxidil. The formulation may comprise no more than 11 wt% minoxidil. The formulation may comprise no more than 10 wt% minoxidil.

[0084] The formulation may comprise 2 to 11 wt% minoxidil. The formulation may comprise 3 to 7 wt% minoxidil. The formulation may comprise 4 to 6 wt% minoxidil. The formulation may comprise 8 to 12 wt% minoxidil. The formulation may comprise 9 to 11 wt% minoxidil.

[0085] The formulation may comprise about 2 wt% minoxidil. The formulation may comprise about 5 wt% minoxidil. The formulation may comprise about 10 wt% minoxidil.

[0086] The formulation may comprise at least 0.1 wt% finasteride. The formulation may comprise at least 0.2 wt% finasteride. The formulation may comprise no more than 0.3 wt% finasteride. The formulation may comprise no more than 0.75 wt% finasteride. The formulation may comprise no more than 1 wt% finasteride.

[0087] The formulation may comprise 0.1 wt% to 1 wt% finasteride. The formulation may comprise 0.2 wt% to 0.6 wt% finasteride. For example, the formulation may comprise 0.25 to 0.5 wt% finasteride.

[0088] The formulation may comprise about 0.25 wt% finasteride.

[0089] The formulation may comprise at least 0.05 wt% melatonin. For example, the formulation may comprise at least 0.1 wt% melatonin. The formulation may comprise no more than 1 wt% melatonin. The formulation may comprise no more than 0.5 wt% melatonin. The formulation may comprise no more than 0.25 wt% melatonin. The formulation may comprise no more than 0.15 wt% melatonin.

[0090] The formulation may comprise 0.05 wt% to 0.25 wt% melatonin. The formulation may comprise about 0.1 wt% melatonin.

[0091] The formulation may comprise 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 0.5 wt% melatonin. For example, the formulation may comprise 0.1 wt% to 0.5 wt% finasteride and 0.05 wt% to 0.1 wt% melatonin.

[0092] The formulation may comprise 2 to 11 wt% minoxidil, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 0.5 wt% melatonin. For example, the formulation may comprise 5 to 10 wt% minoxidil, 0.1 wt% to 0.5 wt% finasteride and 0.05 wt% to 0.1 wt% melatonin.

[0093] In an example, there is provided a formulation comprising 0.25 wt% finasteride and 0.1 wt% melatonin.

[0094] In an example, there is provided a formulation comprising 10 wt% minoxidil, 0.25 wt% finasteride and 0.1 wt% melatonin.

[0095] In an example, there is provided a formulation comprising 5 wt% minoxidil, 0.25 wt% finasteride and 0.1 wt% melatonin.

[0096] In an example, there is provided a formulation comprising 2 wt% minoxidil, 0.25 wt% finasteride and 0.1 wt% melatonin.

[0097] The formulation may further comprise a prostaglandin analogue. For example, the formulation may further comprise a prostaglandin analogue selected from the group consisting of: latanoprost, travoprost, bimatoprost, tafluprost and unoprostone.

[0098] In an example, the formulation further comprises latanoprost.

[0099] The formulation may further comprise a prostaglandin analogue (e.g. latanoprost) at an amount between 0.01 wt% to 5 wt%. For example, the prostaglandin analogue may be present at an amount of 0.1 wt%.

[00100] In an example, the formulation further comprises 0.1 wt% latanoprost.

[00101] The formulation may further comprise a prostaglandin analogue (e.g. latanoprost) at an amount between 0.0001 wt% to 5 wt%. For example, the formulation may further comprise latanoprost at an amount between 0.0001 wt% to 5 wt%. It may be that the latanoprost is present at an amount of 0.0005 wt% to 0.01 wt%. It may be that the latanoprost is present at an amount of 0.001 wt%. It may be that the latanoprost is present at an amount of 0.005 wt%.

[00102] In an example, the formulation further comprises 0.001 wt% latanoprost. Thus, it may be that the formulation comprises 0.01 wt% to 1 wt% finasteride, 0.1 wt% to 1 wt% melatonin, and 0.001 wt% latanoprost. It may be that the formulation comprises 0.01 wt% to 1 wt% finasteride, 0.1 wt% to 1 wt% melatonin, 1 wt% to 12.5 wt% minoxidil, and 0.001 wt% latanoprost.

[00103] In an example, the formulation further comprises 0.005 wt% latanoprost. Thus, it may be that the formulation comprises 0.01 wt% to 1 wt% finasteride, 0.1 wt% to 1 wt% melatonin, and 0.005 wt% latanoprost. It may be that the formulation comprises 0.01 wt% to 1 wt% finasteride, 0.1 wt% to 1 wt% melatonin, 1 wt% to 12.5 wt% minoxidil, and 0.005 wt% latanoprost.

[00104] The formulation may also further comprise a retinoic acid. For example, the formulation may further comprise tretinoin.

[00105] The formulation may further comprise a retinoic acid (e.g. tretinoin) at an amount between 0.01 wt% to 2 wt%. For example, the retinoic acid may be present at an amount of 0.01 wt%.

[00106] In an example, the formulation further comprises 0.01% tretinoin.

[00107] In an example, there is provided a formulation further comprising latanoprost and tretinoin.

[00108] In an example, there is provided a formulation further comprising latanoprost at an amount between 0.01 wt% to 5 wt% and tretinoin at an amount between 0.01 wt% to 2 wt%.In an example, there is provided a formulation comprising 5 wt% minoxidil, 0.25 wt% finasteride, 0.1 wt% melatonin, 0.1 wt% latanoprost and 0.01 wt% tretinoin.

[00109] In an example, there is provided a formulation further comprising latanoprost at an amount between 0.0001 wt% to 5 wt% and tretinoin at an amount between 0.01 wt% to 2 wt%. It may be that the formulation further comprises latanoprost at an amount between 0.0005 wt% to 0.01 wt% and tretinoin at an amount between 0.01 wt% to 2 wt%.

[00110] In an example, the formulation further comprises 0.001 wt% latanoprost and tretinoin at an amount between 0.01 wt% to 2 wt%. Thus, it may be that the formulation comprises 0.01 wt% to 1 wt% finasteride, 0.1 wt% to 1 wt% melatonin, 0.01 wt% to 2 wt% tretinoin, and 0.001 wt% latanoprost. It may be that the formulation comprises 0.01 wt% to 1 wt% finasteride, 0.1 wt% to 1 wt% melatonin, 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 2 wt% tretinoin, and 0.001 wt% latanoprost.

[00111] In an example, the formulation further comprises 0.005 wt% latanoprost and tretinoin at an amount between 0.01 wt% to 2 wt%. Thus, it may be that the formulation comprises 0.01 wt% to 1 wt% finasteride, 0.1 wt% to 1 wt% melatonin, 0.01 wt% to 2 wt% tretinoin, and 0.005 wt% latanoprost. It may be that the formulation comprises 0.01 wt% to 1 wt% finasteride, 0.1 wt% to 1 wt% melatonin, 1 wt% to 12.5 wt% minoxidil, 0.01 wt% to 2 wt% tretinoin, and 0.005 wt% latanoprost.

[00112] The formulation may further comprise ketoconazole and/or spironolactone.

[00113] The formulation may be a pharmaceutical composition.

[00114] Typically, the subject is a human subject.

[00115] The human subject may be male.

[00116] The human subject may be female. However, the formulation is not suitable for pregnant females.

[00117] The formulation may be suitable for all ages of human subject. However, the human subject may be over 18 years old.

[00118] The formulation will typically be administered topically. The formulation will typically be for topical administration.

[00119] The formulation may be administered topically to the subject to areas affected by hair loss. The formulation may be administered topically to the subject in areas of hair thinning. The formulation may be administered topically to the scalp of a human subject.

[00120] The formulation may be administered topically to the eyebrows of a human subject. The formulation may be administered topically to the eyelashes of a human subject.

[00121] The formulation may be administered between one and two times a day. For example, the formulation may be administered once a day. The formulation may be administered twice a day.

[00122] In an example, the formulation may be administered topically to the scalp of a human subject once a day. Preferably, the formulation may be administered topically to the scalp of a human subject at night.

[00123] An amount between 0.5 ml and 3 ml of the formulation may be administered topically to the scalp of the human subject. An amount of about 1 ml of the formulation may be administered topically to the scalp of the human subject.

[00124] For example, an amount of 1 ml of the formulation may be administered topically to the scalp of the human subject once a day at night.

[00125] In an example, the formulation may be administered topically to the eyebrows and/or eyelashes of a human subject once a day. Preferably, the formulation may be administered topically to the eyebrows and/or eyelashes of a human subject at night.

CLAIMS

1. A cosmetic method of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF) comprising administering a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the scalp of the subject.

2. Use of a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin in a cosmetic method to increase hair thickness, increase hair growth, reduce hair thinning and/or reduce hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF).

3. A formulation comprising, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin for the treatment of hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF).

4. Use of a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin, in the manufacture of a medicament for increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF).

5. The cosmetic method, use and/or formulation according to any one of claims 1 to 4, wherein the hair loss is caused by androgenetic alopecia.

6. The cosmetic method, use and/or formulation according to any one of claims 1 to 5, wherein the formulation further comprises 1 wt% to 12.5 wt% minoxidil.

7. The cosmetic method, use and/or formulation according to claim 6, wherein the formulation further comprises 2 wt% to 11 wt% minoxidil.

8. The cosmetic method, use and/or formulation according to any one of claims 1 to 7, wherein the formulation comprises 0.1 wt% to 1 wt% finasteride.

9. The cosmetic method, use and/or formulation according to any one of claims 1 to 8, wherein the formulation comprises 0.05 wt% to 0.5 wt% melatonin.

10. The cosmetic method, use and/or formulation according to any one of claims 1 to 9, wherein the formulation further comprises a prostaglandin analogue at an amount between 0.0005 wt% to 5 wt%

11. The cosmetic method, use and/or formulation according to claim 10, wherein the prostaglandin analogue is selected from the group consisting of: travoprost, bimatoprost, tafluprost and unoprostone.

12. The cosmetic method, use and/or formulation according to claim 10, wherein the prostaglandin analogue is latanoprost.

13. The cosmetic method, use and/or formulation according to any one of claims 1 to 12, wherein the formulation further comprises a retinoic acid at an amount between 0.01 wt% to 2 wt%.

14. The cosmetic method, use and/or formulation according to claim 13, wherein the retinoic acid is tretinoin.

15. The cosmetic method, use and/or formulation according to any one of claims 1 to 14, wherein the formulation is in the form of an ointment, lotion and/or spray for topical administration.

16. The cosmetic method, use and/or formulation according to any one of claims 1 to 15, wherein the formulation is to be administered to the scalp of the subject, and wherein PRF is to be further administered to the scalp of the subject.

17. A cosmetic method of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss of the eyebrows and/or eyelashes of a subject comprising administering a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin to the eyebrows and/or eyelashes of the subject.

18. Use of a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin in a cosmetic method to increase hair thickness, increase hair growth, reduce hair thinning and/or reduce hair loss of the eyebrows and/or eyelashes in a subject.

19. A formulation comprising, 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin for the treatment of hair loss of the eyebrows and/or eyelashes of a subject.

20. Use of a formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin, in the manufacture of a medicament for increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss of the eyebrows and/or eyelashes of a subject.

21. A formulation comprising 0.01 wt% to 1 wt% finasteride and 0.01 wt% to 1 wt% melatonin for use in therapy.